Anika Therapeutics (ANIK) Expected to Announce Quarterly Earnings on Thursday

Anika Therapeutics (NASDAQ:ANIK) is expected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $28.8750 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Anika Therapeutics Stock Performance

Anika Therapeutics stock opened at $10.52 on Thursday. The stock has a market cap of $151.70 million, a P/E ratio of -4.61 and a beta of 0.43. Anika Therapeutics has a fifty-two week low of $7.87 and a fifty-two week high of $18.19. The firm’s fifty day moving average price is $9.66 and its 200-day moving average price is $9.41.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Quarry LP purchased a new stake in shares of Anika Therapeutics in the 3rd quarter valued at $71,000. Occudo Quantitative Strategies LP bought a new stake in Anika Therapeutics in the third quarter worth $95,000. Ieq Capital LLC purchased a new stake in Anika Therapeutics during the fourth quarter valued at about $97,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Anika Therapeutics during the fourth quarter valued at about $122,000. Finally, Jain Global LLC bought a new position in shares of Anika Therapeutics during the fourth quarter valued at about $137,000. 91.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ANIK. Wall Street Zen raised Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Barrington Research reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Anika Therapeutics in a research note on Friday, January 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Anika Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.